Shanghai LePure Biotech Co., Ltd, a China-based biotechnology company, has reportedly raised “hundreds of millions” of renminbi in a Series C financing round. The funding was led by Novo Holdings, General Atlantic, and Goldman Sachs Asset Management, with additional participation from HLC, Bayland Capital, HM Capital, Cas Holding, and TDF Capital. The proceeds will be used to construct research and development (R&D) centers in China and the United States, support talent recruitment, expand overseas business operations, and pursue mergers and acquisitions (M&A) both domestically and internationally.
Company Overview and Strategic Focus
Founded in 2011, LePure Bio has established a strong business layout focusing on Single Use Systems (SUS), filtration, and culture medium consumables. The company has recently acquired QuaCell Biotechnology, Co., Ltd, a culture medium firm based in the Greater Bay Area, further expanding its product portfolio and market reach. This strategic move underscores LePure Bio’s commitment to innovation and growth in the biotech industry.
Future Outlook
The Series C financing round marks a significant milestone for LePure Bio, positioning the company to accelerate its global expansion and enhance its R&D capabilities. With robust financial backing and a clear strategic vision, LePure Bio is poised to make a meaningful impact in the biotechnology sector. The construction of new R&D centers and the focus on talent recruitment will further solidify the company’s position as a leader in Single Use Systems and related technologies.-Fineline Info & Tech
